Minerva Neurosciences (NERV) Total Liabilities (2013 - 2026)

Minerva Neurosciences (NERV) has 14 years of Total Liabilities data on file, last reported at $343.1 million in Q1 2026.

• Quarterly Total Liabilities rose 453.83% year-over-year to $343.1 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $343.1 million (up 453.83% YoY) and the FY2025 annual result came in at $233.8 million, up 272.0% from the prior year.
• Total Liabilities rose to $343.1 million in Q1 2026, from $233.8 million in the prior quarter.
• In the past five years, Total Liabilities ranged from a high of $343.1 million in Q1 2026 to a low of $61.9 million in Q1 2025.
• A 5-year average of $99.4 million and a median of $75.1 million in 2022 frame the typical range for Total Liabilities.
• Annual changes were most pronounced in 2025 — Total Liabilities sank 31.12% — and 2026, when it surged 453.83%.
• Tracing NERV's Total Liabilities over 5 years: stood at $75.1 million in 2022, then gained by 13.64% to $85.4 million in 2023, then dropped by 26.38% to $62.8 million in 2024, then surged by 272.0% to $233.8 million in 2025, then surged by 46.77% to $343.1 million in 2026.
• The last three Total Liabilities figures came in at $343.1 million (Q1 2026), $233.8 million (Q4 2025), and $62.7 million (Q3 2025), per Business Quant data.